On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance bonds due next year and extend a revolving ...

La farmacéutica española Grifols SA está en conversaciones con bancos para refinanciar bonos que vencen el próximo año y ...

For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over ...

The Grifols family won’t support a new bid by a third-party to take its namesake drug-maker private amid indications that ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Grifols (GRFS) stock dropped as Brookfield Asset Management (BAM) is reportedly withdrawing its offer to take the plasma ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Brookfield Asset Management has walked away from an acquisition of Spanish healthcare group Grifols after months of negotiations, sending shares in the short seller target down almost 13 per cent.

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...